I really don't think the current management is the problem, although it would be nice to know who is CYDY's point person responsible for interacting with the FDA.
The FDA's slapdown statement to CYDY was warranted in the FDA's eyes due to the statements and videos made by inexperienced management personnel who are no longer with CYDY. Enough time has passed with new management in place to proceed but the hold is still in place. Whatever that obstruction to lifting the hold is pretty significant as it appears to have perhaps cost CA his health for a while.
Directly interacting with the FDA with communications from us would probably be a waste of time. Kind of like when you interacted with CYDY IR and was made to feel irrelevant.
Asking relevant governmental entities like Senators and Representatives who are on the health sub-committees to look into why Leronlimab is being held up may remind the FDA that they are not really operating in a vacuum, although they probably are. It is one action Longs could undertake.
Or we can wait. Leronlimab can sit on the shelf while the share price is dropping below 2 thin dimes/share.
I've been invested in a couple of other stocks where the situations were at a standstill for months when something out of left field happens and the company/drug became very successful. I think CYDY will do that also. We might be able to help...